Investigational drug · Phase 2
BMS-986517
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumours.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BMS-986517"
First trial start
2025
Oct 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986517", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumours
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986517" as an intervention, largest first.
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07160725 · 540 participants (planned) · Start Oct 15, 2025 · Primary completion Jul 31, 2028
Drug: BMS-986517; Pumitamig · For: Solid Tumours
Sites: Irvine, California; Los Angeles, California; Orange, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumours
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
- ODM-212Phase 22 trials
Orion Corporation, Orion Pharma · Solid Tumours, Mesothelioma, Pancreatic Cancer
- AZD4956Phase 21 trial
AstraZeneca · Solid Tumours
- EP0089-101Phase 21 trial
Ellipses Pharma · Solid Cancers, Solid Tumours
- GSK5864399Phase 21 trial
GSK · Solid Tumours
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.